Functional Assays Of Immunity To Malaria In Pregnant Women
Funder
National Health and Medical Research Council
Funding Amount
$578,905.00
Summary
Pregnant women are highly susceptible to malaria due to the adhesion of infected erythrocytes to the placenta. Antibodies to these infected erythrocytes can block their placental adhesion and/or facilitate their clearance by immune cells, improving pregnancy outcomes. We aim at informing vaccine design by better understanding the placental adhesion mechanisms and identifying targets of protective immunity as well as antibody correlates of protection from placental malaria and its consequences.
Targeting Schistosome Calcium Signalling To Improve And Broaden Praziquantel Efficacy
Funder
National Health and Medical Research Council
Funding Amount
$481,661.00
Summary
Schistosomiasis is caused by parasitic worms, treatment relies solely on praziquantel (PZQ). Schistosomes respond and recover from PZQ exposure through modulation of the gene CamKII. We will target this gene to both increase and extend the efficacy of PZQ in both adult parasites and in refractory juvenile parasites. Research will expand into assaying CamKII inhibitors to maximise effectiveness and take this work into animal models of this disease.
This an integrated program of basic research on antigen discovery and immune mechanisms, and preclinical research on novel vaccine platforms, formulations or delivery systems for the rational design and clinical testing of a next generation vaccine against malaria. This interdisciplinary research fosters strong national and international links and offers the potential for significant economic benefit to Australia.
Investigating The Therapeutic Potential Of FTY720 For Human African Trypanosomiasis
Funder
National Health and Medical Research Council
Funding Amount
$653,736.00
Summary
FTY720, is a drug currently used to treat multiple sclerosis, which we have shown is also be able to kill the parasite responsible for African sleeping sickness, Trypanosomes. We aim to identify the target the drug acts on in the parasite to have its affect. Our objective is to improve the activity further by chemical modification to produce a potent, orally available and well characterised, non-toxic drug suitable for preclinical development.